CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
− To understand and address, through clinical and translational research, the disease burden associated with solid tumours and haematological malignancies treated with radiotherapy in Canada.
− To review recent developments in the understanding of molecular biology of cancers treated with radiotherapy.
− To update, review, and discuss recent results of clinical studies involving radiotherapy conducted by the Canadian Cancer Trials Group or national/international collaborators.
− To provide mentoring opportunities for investigators new to clinical trial research.
− To understand and apply new clinical trial methodologies in the field of clinical research.

8:00 am Welcome
M. McKenzie

Updates on CCTG studies pending of activation
8:05 am Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Maintenance Durvalumab vs Durvalumab plus RT followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC). HN.9
K. Sultanem

8:15 am A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVAIDER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma. HN.10
S. Bratman

8:25 am TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer. MA.39
T. Whelan

8:35 am A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases CE.7
D. Roberge

CCTG Led Closed trials
8:45 am HDR brachytherapy in intermediate risk CaP. PR.15
E. Vigneault

continued on next page …
**CCTG Led Open trials**

8:55 am  Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer. **PR.19**

G. Morton/ E. Vigneault

9:05 am  Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer. **HE.1**

L. Dawson

9:15 am  SBRT vs. Conventional Palliative Radiotherapy for Spinal Metastases. **SC.24**

A. Sahgal

9:25 am  Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in BRAF Mutation–Positive Malignant Melanoma and brain metastases. **IND.224**

A. Sahgal

**CCTG Intergroup Open trials**

9:35 am  Preoperative Chemoradiotherapy vs. Preoperative Chemotherapy for Resectable Gastric Cancer. **GA.1**

R. Wong / J. Ringash

9:40 am  Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases. **CEC.5**

N. Laperriere

9:45 am  **Coffee Break**

**Updates on previously discussed studies/ proposals**

10:00 am  Phase II of Immunotherapy +/- Stereotactic Body Radiotherapy for Metastatic Soft Tissue Sarcoma

P. Wong

10:05 am  New Study proposals

10:05 am  External Beam Radiotherapy + Brachytherapy boost vs External Beam Radiotherapy + HDR Brachy boost + short course hormonal therapy for intermediate risk prostate cancer

T. Niazi

10:15 am  RADBRI: SBRT prior to liver transplantation for hepatocellular carcinoma versus no intervention in patients not eligible to transarterial

L. Dawson

10:25 am  Phase II comparing 3- v.s. 5- fraction SBRT in Renal Cell Carcinoma

W. Chu

10:35 am  Randomized Phase II Trial of Local Ablative Therapy for Hormone-Sensitive Oligometastatic Prostate Cancer

P. Cheung

10:45 am  EMBRACE II: Single arm study of image-guided IMRT and adaptive brachytherapy plus chemotherapy in advanced cervix cancer

I. Fortin

10:55 am  5STAR: 5 fractions of pelvic SABR with intraprostatic SABR boost

A. Loblaw

11:05 am  SBRT: Where to house SBRT protocols

R. Wong

11:15 am  Post operative SBRT for spinal metastasis comparing conventional radiation therapy (20Gy/5 fx) vs SBRT

L. Masucci

11:25 am  Activities of the Radiation Oncology Quality Assurance Committee

A. Nichol

11:35 am  CCTG Radiotherapy Strategic Agenda

M. McKenzie/ W. Parulaker

12:00 pm  **Meeting adjourned.**